Orexin-agonist treatments for sleep disorders and their wider implications are introduced alongside several science news briefs to pique curiosity.
Key Takeaways
- Targets a root cause of narcolepsy by activating receptors that respond to the peptide orexin
- GLP-1s were originally used to treat diabetes and obesity
- In the meantime, most postdocs whose fellowships have come to an end won’t get paid